Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | POLB | P06746 | 1/20 | 0.85 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.85 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.85 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.85 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.81 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.81 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114942 | 0.98 | CHRNA7 (0.85) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Dimethylphenylpiperazinium SCHEMBL305083 | 0.92 | MEN1 (1.00) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Dimethylphenylpiperazinium SCHEMBL3453554 | 0.90 | CHRNA7 (1.00) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Dimethylphenylpiperazinium SCHEMBL6829257 | 0.88 | CHRNA7 (0.96) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Dimethylphenylpiperazinium SCHEMBL1427906 | 0.88 | CHRNA7 (0.96) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL6748684 | 0.80 | MAPT (0.58) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL17151056 | 0.80 | HTR3E (0.59) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Hydrochloric Acid SCHEMBL5354549 | 0.79 | MAPT (0.56) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL18999281 | 0.79 | CHRNA7 (0.64) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Iodide SCHEMBL17144379 | 0.78 | KMT2A (0.57) | MEN1POLBAPOBEC3APMP22KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125903-B1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | UNIV LAVAL (CA) | 2018-12-19 | — | — | EP | disclosed |
| US-20180235978-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | UNIVERSITé LAVAL (CA) | 2018-08-23 | — | — | US | disclosed |
| US-9949984-B2 | Method for use of homopiperazinium compounds in the treatment of cancer | UNIVERSITé LAVAL (CA) | 2018-04-24 | — | — | US | disclosed |
| US-20170173040-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | UNIVERSITé LAVAL (CA) | 2017-06-22 | — | — | US | disclosed |
| EP-1773779-B1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV LAVAL (CA) | 2013-12-04 | — | — | EP | disclosed |
| US-8557804-B2 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2013-10-15 | — | — | US | disclosed |
| US-8551983-B2 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2013-10-08 | — | — | US | disclosed |
| US-20120022049-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2012-01-26 | — | — | US | disclosed |
| US-8039459-B2 | especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids | UNIVERSITE LAVAL (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20080221085-A1 | Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases | UNIVERSITE LAVAL (CA) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173040-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | HCCS, XDH, XPA | MEN1 908/4885POLB 614/4885APOBEC3A 2787/4885 |
| US-20180235978-A1 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | MGMT, KAT5, KAT2B | MEN1 198/4885POLB 1188/4885APOBEC3A 3490/4885 |
| US-20080221085-A1 | Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases | CHRNA1, CHRNG, CHRM1 | MEN1 3942/4885POLB 3368/4885APOBEC3A 4191/4885 |
| US-20120022049-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CHRNA1, CHRNG, CHRM1 | MEN1 3942/4885POLB 3368/4885APOBEC3A 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.